Activation of FIP1L1-PDGFR requires disruption of the juxtamembrane domain of PDGFR and is FIP1L1-independent
نویسندگان
چکیده
*Division of Hematology, Department of Medicine, and ¶Department of Pathology, Brigham and Women’s Hospital, †Department of Genetics, and **Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115; ‡Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322; §Department of Human Genetics, Flanders Interuniversity Institute for Biotechnology (VIB), University of Leuven, 3000 Leuven, Belgium; and Department of Pathology, Emory University, Atlanta, GA 30322
منابع مشابه
Sorafenib is a potent inhibitor of FIP1L1-PDGFR and the imatinib-resistant FIP1L1-PDGFR T674I mutant
The FIP1L1-PDGFRA oncogene is a common cause of chronic eosinophilic leukemia (CEL), and encodes an activated tyrosine kinase that is inhibited by imatinib. FIP1L1PDGFRA–positive patients with CEL respond to low-dose imatinib therapy, but resistance due to acquired T674I mutation has been observed. We report here the identification of sorafenib as a potent inhibitor of the FIP1 like 1–platelet-...
متن کاملThe small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFR and FIP1L1-PDGFR in vitro and in vivo
AMN107 is a small molecule tyrosine kinase inhibitor developed, in the first instance, as a potent inhibitor of breakpoint cluster region-abelson (BCR-ABL). We tested its effectiveness against fusion tyrosine kinases TEL–platelet-derived growth factor receptor (TEL-PDGFR ) and FIP1-like-1 (FIP1L1)–PDGFR , which cause chronic myelomonocytic leukemia and hypereosinophilic syndrome, respectively. ...
متن کاملFIP1L1/PDGFR -Associated Systemic Mastocytosis
Since the identification of the FIP1L1/PDGFRA fusion gene as a pathogenic cause of the hypereosinophilic syndrome (HES), the importance of the molecular classification of HES leading to the diagnosis of chronic eosinophilic leukemia (CEL) has been recognized. As a result, a new category, ‘myeloid and lymphoid neoplasm with eosinophilia and abnormalities in PDGFRA, PDGFRB or FGFR1’, has recently...
متن کاملCHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
Imatinib mesylate is effective in the treatment of hematologic malignancies that are characterized by either abl- or PDGFR beta- activating mutations. The drug is also active in a subset of patients with eosinophilic disorders and systemic mast cell disease (SMCD). Recently, a novel tyrosine kinase that is generated from fusion of the Fip1-like 1 (FIP1L1) and PDGFR alpha (PDGFRA) genes has been...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
Imatinib mesylate is effective in the treatment of hematologic malignancies that are characterized by either ablor PDGFR activating mutations. The drug is also active in a subset of patients with eosinophilic disorders and systemic mast cell disease (SMCD). Recently, a novel tyrosine kinase that is generated from fusion of the Fip1-like 1 (FIP1L1) and PDGFR (PDGFRA) genes has been identified as...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2006